Search results for "Coagulation"

showing 10 items of 381 documents

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism

2019

Abstract Introduction VTE‐BLEED is a validated score for identification of patients at increased risk of major bleeding during extended anticoagulation for venous thromboembolism (VTE). It is unknown whether VTE‐BLEED high‐risk patients also have an increased risk for recurrent VTE, which would limit the potential usefulness of the score. Methods This was a post hoc analysis of the randomized, double‐blind, placebo‐controlled PADIS‐PE trial that randomized patients with a first unprovoked pulmonary embolism (PE) initially treated during 6 months to receive an additional 18‐month of warfarin vs. placebo. The primary outcome of this analysis was recurrent VTE during 2‐year follow‐up after ant…

medicine.medical_specialtyrecurrencemedicine.drug_classvenous thromboembolismInternal medicinemedicineCumulative incidencecardiovascular diseasesanticoagulation therapylcsh:RC633-647.5business.industryAnticoagulantHazard ratioWarfarinlcsh:Diseases of the blood and blood-forming organsprediction scoreHematologyBleedbleedingequipment and suppliesmedicine.diseaseConfidence intervalPulmonary embolismDiscontinuationOriginal ArticlebusinessOriginal Articles: Thrombosismedicine.drugResearch and Practice in Thrombosis and Haemostasis
researchProduct

Advances in surfaces and osseointegration in implantology. Biomimetic surfaces

2015

The present work is a revision of the processes occurring in osseointegration of titanium dental implants according to different types of surfaces -namely, polished surfaces, rough surfaces obtained from subtraction methods, as well as the new hydroxyapatite biomimetic surfaces obtained from thermochemical processes. Hydroxyapatite’s high plasma-projection temperatures have proven to prevent the formation of crystalline apatite on the titanium dental implant, but lead to the formation of amorphous calcium phosphate (i.e., with no crystal structure) instead. This layer produce some osseointegration yet the calcium phosphate layer will eventually dissolve and leave a gap between the bone and …

medicine.medical_treatmentDentistryintegrationReviewcoatingsApatitelaw.inventionlawBiomimetic MaterialsImplants surfacesbioactive titaniumBiomimetics surfacesAmorphous calcium phosphateComposite materialCrystallizationDental implantTitaniumSuperfícies biomimètiquesImplantes dentalesSuperfícies d’implants:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludbone-formation adjacentSuperficies biomiméticasvisual_artUNESCO::CIENCIAS MÉDICASvisual_art.visual_art_mediumacidvivoLayer (electronics)biomimetics surfacesTitaniumMaterials scienceSurface Propertiesproliferationchemistry.chemical_elementOdontología616.3in-vitro:Enginyeria dels materials [Àrees temàtiques de la UPC]OsseointegrationBacterial colonizationfibronectinOsseointegrationmedicineAnimalsHumansGeneral DentistryBlood CoagulationDental ImplantsOral Medicine and PathologyImplants dentalsbusiness.industryDental implantsosseointegrationTitaniimplants surfacesSuperficies de implantesOtorhinolaryngologychemistryOsteointegraciónSurgerybusinessOsteointegració
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

2017

BACKGROUND: GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available.OBJECTIVES: This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1.METHODS: During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis des…

oral anticoagulationCross-Sectional StudieMaleRegistrieFibrinolytic AgentInternationalityAntithrombinMedizinregistryMiddle AgedAntithrombinsDabigatranStrokeProspective StudieCross-Sectional StudiesFibrinolytic AgentsAtrial FibrillationJournal ArticleHumansFemaleProspective StudiesRegistriesCardiology and Cardiovascular MedicineAgedHuman
researchProduct

Dental treatment of patients with coagulation factor alterations: An update

2007

Hemostasia is a defense mechanism that protects vascular integrity, avoids blood loss, and maintains blood fluidity throughout the circulatory system. The biochemical processes leading to blood clot formation are complex, and alterations can appear at any point within the chain of events. While a range of alterations can affect the coagulation factors, some are more common than others in the general population, including congenital (hemophilia A and B, Von Willebrand’s disease) and acquired disorders (anticoagulant drugs). Such diseases require special consideration in the context of dental treatment, and therefore must be known to dental professionals. Interconsultation with the hematologi…

prevencióninterconsultaanticoagulant drugscoagulation factors:CIENCIAS MÉDICAS [UNESCO]hemofiliapreventionVon Willebrand’s diseasehemophiliaUNESCO::CIENCIAS MÉDICASfactores de coagulaciónHemostasiaenfermedad de von WillebrandVon Willebrand’s diseasefármacos anticoagulantesaccidentes hemorrágicosinterconsultationbleeding accidents
researchProduct

Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements

2022

C. difficile enterocolitis (CDAC) is the most common hospital infection, burdened by an increased incidence of coagulation-related complications such as deep vein thrombosis (DVT) and disseminated intravascular coagulation (DIC) as well as a significant sepsis-related mortality. In this review, we analyzed the available data concerning the correlation between coagulation complications related to C. difficile infection (CDI) and inflammasome activation, in particular the pyrin-dependent one. The little but solid available preclinical and clinical evidence shows that inflammasome activation increases the risk of venous thromboembolism (VTE). As proof of this, it has been observed that in vitr…

sepsisMicrobiology (medical)enterocolitiinduced inflammasome activationcoagulation derangementVirologyClostridium difficileMicrobiologyMicroorganisms
researchProduct

A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation

2022

Venous thromboembolism (VTE) is a life-threatening complication, especially in case of recurrence. The appropriate duration of anticoagulant treatment following the first event is crucial. Risk factors that increase the risk of recurrence of VTE are many, and include medications, kidney disease, renal transplantation (RT), and a diagnosis of sickle cell disease (SCD). There are currently no guidelines that define the duration of anticoagulant therapy after the first event in a patient with RT. We report a case of recurring episodes of VTE after RT in a SCD patient. Our case suggests that the use of a long-term anticoagulant treatment may be recommended in patients with SCD and RT after the …

sickle cellthromboemolismSettore MED/09 - Medicina Internarenal transplantationanticoagulationThalassemia Reports
researchProduct

Use of Fe and Al containing electrocoagulation sludge as an adsorbent and a catalyst in water treatment

2023

In this study, three different electrocoagulation (EC) sludges were studied as an adsorbent (removal of humic acids) and as a catalyst [catalytic wet peroxide oxidation (CWPO) of bisphenol A (BPA)]. The sludges originated from electrocoagulation process in which aluminum (Al) and iron (Fe) electrodes were used for the treatment of mining industry wastewater. All the materials were used as dried sludge and calcined material. The stability of these materials was studied in neutral and alkaline conditions with analysis of the leached iron content in solution. Based on the EC sludge characterization with X-ray fluorescence (XRF), X-ray diffractometer (XRD), and diffuse-reflectance infrared Four…

sähkösaostusEnvironmental Engineeringcircular economyutilizationjätevesilieteadsorbentkatalyytitsludgeelectrocoagulationkiertotalousextractionteollisuusjätevesiEnvironmental Chemistryhyötykäyttöadsorptiojäteveden käsittelyGeneral Environmental ScienceCivil and Structural Engineeringcatalyst
researchProduct

Genetic Factors as Promising Biomarkers of Sporadic Ascending Aortic Aneurysm

2014

Thoracic aorta shows various changes with advancing age and a progressive deterioration in structure and function. As a result, vascular remodeling (VR) and medial degeneration (MD) occur. VR and MD are typical entities of sporadic thoracic aortic aneurysm (TAA), actually considered a common and serious health risk and a pathology by unclear mechanisms. Increased activity of the coagulation system, inflammation, activation of extracellular matrix remodeling and endothelial dysfunction pathways have been recently evidenced to have a key role in its onset. Thus, polymorphisms of the coagulation system [fibrinogen (rs1800790); Factor II ( rs1799963); Factor V (rs6025); Factor VII (rs121964926)…

tPA ( rs2020918)ACE (rs1799752)]PAI-1 (rs1799768)TAFI (rs2146881)] inflammation [TLR4 (rs4986790)Factor V (rs6025)CCR5 (rs333)] extra-cellular matrix remodeling [MMP9 (rs3918242)vascular remodeling (VR) and medial degeneration (MD)sporadic thoracic aortic aneurysm (TAA)polymorphisms of the coagulation system [fibrinogen (rs1800790)MMP2 (rs243865)] endothelium dysfunction [eNOs (rs 1799983)Factor II ( rs1799963)Factor VII (rs121964926)
researchProduct